The Toronto Memory Program (TMP) is the first clinic in Canada to offer C2N Diagnostics’ PrecivityAD2 blood test for Alzheimer’s disease. This non-invasive test detects amyloid pathology, a hallmark of Alzheimer’s, and addresses the diagnostic challenges posed by limited access to specialists and infrastructure like PET scanners. The test is designed for individuals aged 55 and older experiencing cognitive decline and suspected of having Alzheimer’s or other related conditions.
This development significantly impacts Alzheimer’s care in Canada, where over 600,000 individuals live with the disease and many more experience mild cognitive impairment. The lengthy wait times for diagnosis, primarily due to limited resources, hinder timely intervention and treatment. The PrecivityAD2 test offers a more accessible and efficient diagnostic pathway, potentially expediting diagnosis and enabling earlier access to emerging treatments.
The PrecivityAD2 test requires a simple blood draw and measures specific proteins associated with amyloid plaques in the brain. A recent study published in JAMA demonstrated the test’s high accuracy, exceeding 90% when compared to traditional methods like cerebrospinal fluid analysis and amyloid PET scans. The test is performed in C2N’s certified and accredited laboratory, adhering to rigorous quality standards.
The introduction of the PrecivityAD2 test in Canada represents a crucial step toward improving Alzheimer’s care. Wider availability of this blood test promises to reduce diagnostic delays, facilitate earlier and more accurate diagnoses, and ultimately enhance patient care by enabling timely access to appropriate interventions and therapies. This also opens doors for more efficient clinical trials and research into Alzheimer’s disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
